Last updated: Oct 15, 2026 · Built by a patient who got tired of scrolling ClinicalTrials.gov
Active interventional trials with status RECRUITING or NOT_YET_RECRUITING. A multi-phase trial (e.g. 1/2) is counted in each of its phases.
Biomarkers, stage, prior treatments — get a ranked shortlist in minutes.
Recruiting trials grouped by drug class. Trials with unclassifiable or non-therapeutic interventions are excluded from this view.
| NCT | Phase | Title | Mechanism |
|---|---|---|---|
| NCT07028853 | 3 | This Study Will Explore Whether a Combination of the Investigational Drug Mevrometostat (PF-06821497) and Enzalutamide Will Work Better Than Taking Enzalutamide Alone in Participants With mCSPC Who Are ARPI naïve. | EZH2 -- methyltransferase inhibitor (small molecule) |
| NCT06325046 | — | Adaptive Radiation Therapy (ART) Stereotactic Ablative Body Radiotherapy (SABR) for Primary Localized Prostate Cancer | Non-therapeutic |
| NCT05691465 | 2 | Testing the Safety and Effectiveness of Radiation-based Treatment (Lutetium Lu 177 Dotatate) for Metastatic Prostate Cancer That Has Neuroendocrine Cells | Somatostatin receptor -- targeted radioligand therapy (radiopharmaceutical) |
| NCT06629779 | 3 | A Study to Learn How PF-06821497 (Mevrometostat) Works in Men With Metastatic Castration-resistant Prostate Cancer. | EZH2 -- methyltransferase inhibitor + Androgen receptor -- antagonist (AR inhibitor) |
| NCT06952803 | 3 | A Study of Metastases Free Survival With Saruparib vs Placebo Added to a Standard RT/ADT in Men With High-risk Prostate Cancer With a BRCA Mutation | PARP -- PARP inhibitor |
| Sponsor | Recruiting trials |
|---|---|
| University Health Network, Toronto | 21 |
| M.D. Anderson Cancer Center | 17 |
| Memorial Sloan Kettering Cancer Center | 14 |
| National Cancer Institute (NCI) | 13 |
| Mayo Clinic | 13 |
Countries/regions with the most active trial sites for prostate cancer. A multi-site trial is counted once per country/region.
Phase-1 trials whose listed start date falls within the last 12 months — the leading edge of the field.
| Start | NCT | Title | Mechanism |
|---|---|---|---|
| Mar 2028 | NCT05896371 | A Phase 1/2 Study of Personalized PSMA Radiopharmaceutical Therapy | Prostate-specific membrane antigen (PSMA) -- radioligand therapy with lutetium-177 labeled PSMA ligand |
| Dec 31, 2026 | NCT04429451 | PSMA-specific CAR-T Cell Therapy | PSMA -- chimeric antigen receptor T cell therapy (CAR-T) |
| Nov 30, 2026 | NCT07756593 | Sipuleucel-T (Sip-T) in Combination With N-803 in Metastatic Androgen Pathway Modulation Resistant (mAPMR) Prostate Cancer | Prostate cancer antigens -- autologous cellular immunotherapy (Sipuleucel-T) + IL-15 superagonist -- immune activation (N-803) |
| Nov 1, 2026 | NCT07796490 | Neoadjuvant Intraprostatic OnabotulinumtoxinA Before Radical Prostatectomy for High-Risk Localized Prostate Cancer | SNARE proteins -- neurotoxin inhibiting neurotransmitter release (botulinum toxin) |
| Nov 2026 | NCT07730125 | Gene-edited T Regulatory Cells (CRG-150) for the Treatment of Relapsed/Refractory Malignancies | Regulatory T cells -- gene-edited cell therapy |
| Oct 31, 2026 | NCT07803653 | IL-18 Armored STEAP1 CAR T Cells for the Treatment of Metastatic Castration Resistant Prostate Cancer | STEAP1 -- chimeric antigen receptor (CAR) T cell therapy armored with IL-18 cytokine |
| Oct 19, 2026 | NCT07667400 | Docetaxel and SX-682 in Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma, Salivary Gland Carcinoma, and Advanced Prostate Cancer | CXCR1/2 -- small molecule antagonist (chemokine receptor inhibitor) |
| Oct 12, 2026 | NCT07871435 | GI-102 (CD80-IgG4 Fc-IL2v3) in Combination With Pasritamig in Patients With Metastatic Castration-resistant Prostate Cancer (mCRPC) (JET-201) | CD80 + IL-2 variant fusion protein -- immune costimulatory agonist (fusion protein) |
You've seen the prostate cancer landscape. Now find the trials that fit your case.
Enter biomarkers, stage, and prior treatments — get ranked matches with eligibility breakdown in minutes.
Find My Matches →Source: ClinicalTrials.gov, synced daily. Aggregated by ClinTrialFinder.